Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

VMR tied to severe COPD exacerbation

Visceral fat-to-muscle ratio (VMR) can be used to predict the severe exacerbation of chronic obstructive pulmonary disease (COPD), suggests a study.

VMR tied to severe COPD exacerbation

Neonatal vitamin D status linked to mental disorder risks

Individuals with vitamin D deficiency as neonates face a heightened risk of mental disorders, according to a study.

Neonatal vitamin D status linked to mental disorder risks

HF hospitalization risk greater in IMID patients

Patients with immune-mediated inflammatory disease (IMID) are at increased risk of hospitalization for heart failure (HF) when compared to the general population, reveals a study.

HF hospitalization risk greater in IMID patients

Low HDL-C levels may heighten risk of acromegaly

Individuals with low high-density lipoprotein cholesterol (HDL-C) levels face an increased risk of acromegaly, according to a large retrospective study from Korea.

Low HDL-C levels may heighten risk of acromegaly

Plant-based fasting-mimicking diet does not boost medication response in UC

The low-calorie, plant-based fasting-mimicking (LC-PB) diet does little to improve clinical response to medications in patients with active ulcerative colitis (UC), according to a study. However, LC-PB diet helps with steroid tapering and reduce serum amyloid A.

Plant-based fasting-mimicking diet does not boost medication response in UC

Linerixibat quells cholestatic itch in PBC, enabling better sleep

23 May 2025 bởi

The ileal bile acid transporter inhibitor linerixibat provides rapid and substantial relief from cholestatic pruritus, in turn reducing associated sleep disturbances, in patients with primary biliary cholangitis (PBC), as shown in the global, phase III GLISTEN trial.

Linerixibat quells cholestatic itch in PBC, enabling better sleep

23 May 2025

Adverse events push RA-ILD patients to discontinue nintedanib

In patients with rheumatoid arthritis (RA)-related interstitial lung disease (ILD), combination therapy with disease-modifying antirheumatic drugs (DMARDs) does not negatively influence the safety and efficacy of nintedanib, reports a study. The main drivers of drug withdrawal or dose reduction in these individuals are adverse events (AEs), primarily due to comorbidities.

Adverse events push RA-ILD patients to discontinue nintedanib

Tirzepatide boasts lower risk of GI side effects vs other GLP1-RAs

23 May 2025 bởi

The use of tirzepatide delivers a better safety profile when compared to other glucagon-like peptide-1 receptor agonists (GLP-1RAs), as shown by the lower risk of gastrointestinal (GI) side effects associated with its use, reports a real-world study presented at DDW 2025.

Tirzepatide boasts lower risk of GI side effects vs other GLP1-RAs